Clinical trial

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

NCT07216391

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-07-29

PhasePHASE2

Study timeline

Study start (actual)2026-07-29Date precision: day

Registry last updated2026-09-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 1 Diabetes Mellitusunresolved

Interventions

Antithymocyte Globulin (ATG)DRUG

TeplizumabDRUG · verified · RxNorm: teplizumab

Sponsors & collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)lead sponsor

Mapped research locations

New YorkNew York, United States1 SeattleWashington, United States1 PittsburghPennsylvania, United States1 AuroraColorado, United States1 New HavenConnecticut, United States1 GainesvilleFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07216391 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.